Vanguard Personalized Indexing Management LLC Buys 5,763 Shares of DexCom, Inc. $DXCM

Key Points

• Vanguard Personalized Indexing Management LLC increased its stake in DexCom, Inc. by 15.0%, acquiring an additional 5,763 shares, bringing its total holdings to 44,260 shares valued at approximately $3.86 million.
• Various hedge funds, including Nuveen LLC and Jennison Associates LLC, have significantly increased their positions in DexCom, indicating strong institutional interest with 97.75% of shares currently held by institutional investors.
• DexCom's stock recently received multiple rating upgrades from analysts, with targets raised by firms including Piper Sandler and Morgan Stanley, signaling confidence in the company's future performance.

Vanguard Personalized Indexing Management LLC lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 15.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 44,260 shares of the medical device company's stock after acquiring an additional 5,763 shares during the quarter. Vanguard Personalized Indexing Management LLC's holdings in DexCom were worth $3,864,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in DXCM. Nuveen LLC bought a new position in shares of DexCom during the 1st quarter valued at approximately $554,893,000. Jennison Associates LLC grew its stake in shares of DexCom by 37.7% during the 1st quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company's stock valued at $718,632,000 after acquiring an additional 2,879,489 shares during the period. Massachusetts Financial Services Co. MA grew its stake in shares of DexCom by 171.0% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 3,194,829 shares of the medical device company's stock valued at $218,175,000 after acquiring an additional 2,015,971 shares during the period. Federated Hermes Inc. grew its stake in shares of DexCom by 2,371.4% during the 1st quarter. Federated Hermes Inc. now owns 1,994,732 shares of the medical device company's stock valued at $136,220,000 after acquiring an additional 1,914,019 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in DexCom by 22.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company's stock worth $691,336,000 after purchasing an additional 1,868,241 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 1,466 shares of the firm's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $80.00, for a total transaction of $117,280.00. Following the sale, the executive vice president owned 105,223 shares of the company's stock, valued at $8,417,840. This trade represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mark G. Foletta sold 2,750 shares of the firm's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $81.06, for a total value of $222,915.00. Following the sale, the director directly owned 51,121 shares in the company, valued at approximately $4,143,868.26. The trade was a 5.10% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 6,849 shares of company stock worth $564,733. Corporate insiders own 0.32% of the company's stock.

Wall Street Analysts Forecast Growth

DXCM has been the subject of several recent analyst reports. Weiss Ratings restated a "hold (c-)" rating on shares of DexCom in a research note on Wednesday, October 8th. Morgan Stanley upped their price target on DexCom from $82.00 to $89.00 and gave the stock an "equal weight" rating in a research note on Tuesday, July 15th. Piper Sandler increased their target price on DexCom from $90.00 to $100.00 and gave the company an "overweight" rating in a research report on Thursday, July 31st. William Blair upgraded DexCom to a "strong-buy" rating in a research report on Thursday, July 31st. Finally, Barclays increased their target price on DexCom from $93.00 to $98.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 30th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat, DexCom currently has a consensus rating of "Moderate Buy" and an average target price of $97.42.

DexCom Stock Performance

NASDAQ:DXCM opened at $66.21 on Wednesday. The stock's fifty day moving average is $74.01 and its 200 day moving average is $77.62. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25. The firm has a market capitalization of $25.96 billion, a PE ratio of 45.98, a PEG ratio of 1.37 and a beta of 1.47. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the prior year, the firm posted $0.43 EPS. DexCom's quarterly revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.